MiMedx Group, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
MiMedx Group, Inc. (MDXG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $200.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-25
- MiMedx Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-12-31 was $505.06K, a 58.48% decline year-over-year.
- MiMedx Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-09-30 was $4.89M, a 1315.40% increase year-over-year.
- MiMedx Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-06-30 was $11.44M, a 2200.52% increase year-over-year.
- MiMedx Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-03-31 was $1.67M, a 62.49% decline year-over-year.
- MiMedx Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $200.00K, a 0.00% change from fiscal 2023.
- MiMedx Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $200.00K, a 66.67% decline from fiscal 2022.
- MiMedx Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $600.00K, a 81.82% decline from fiscal 2021.
- MiMedx Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $3.30M, a 73.68% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $200.00K 10-K · filed 2026-02-25 | ||||
| 2023-12-31 | $200.00K 10-K · filed 2026-02-25 | ||||
| 2022-12-31 | $600.00K 10-K · filed 2025-02-26 | ||||
| 2021-12-31 | $3.30M 10-K · filed 2024-02-28 | ||||
| 2020-12-31 | $1.90M 10-K · filed 2023-02-28 | ||||
| 2019-12-31 | $600.00K 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | $7.90M 10-K · filed 2021-03-08 | ||||
| 2017-12-31 | $505.06K derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-06 | $5.40M derived: sum of 2 quarters · filed 2020-07-06 | $16.83M derived: sum of 3 quarters · filed 2020-07-06 | $18.50M 10-K · filed 2020-07-06 | |
| 2017-09-30 | $4.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $16.33M derived: sum of 2 quarters · filed 2017-10-31 | $17.99M 10-Q · filed 2017-10-31 | $19.21M derived: sum of 4 quarters · filed 2020-03-17 | |
| 2017-06-30 | $11.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-31 | $13.10M 10-Q · filed 2017-07-31 | $14.32M derived: sum of 3 quarters · filed 2020-03-17 | $14.67M derived: sum of 4 quarters · filed 2020-03-17 | |
| 2017-03-31 | $1.67M 10-Q · filed 2017-05-01 | $2.88M derived: sum of 2 quarters · filed 2020-03-17 | $3.23M derived: sum of 3 quarters · filed 2020-03-17 | $3.72M derived: sum of 4 quarters · filed 2020-03-17 | |
| 2016-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-17 | $1.56M derived: sum of 2 quarters · filed 2020-03-17 | $2.06M derived: sum of 3 quarters · filed 2020-03-17 | $6.50M 10-K · filed 2020-03-17 | $6.46M 10-K · filed 2017-03-01 |
| 2016-09-30 | $345.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $842.75K derived: sum of 2 quarters · filed 2016-11-08 | $5.28M 10-Q · filed 2016-11-08 | $8.06M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2016-06-30 | $497.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-02 | $4.94M 10-Q · filed 2016-08-02 | $7.72M derived: sum of 3 quarters · filed 2017-03-01 | $10.91M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2016-03-31 | $4.44M 10-Q · filed 2016-05-10 | $7.22M derived: sum of 2 quarters · filed 2017-03-01 | $10.41M derived: sum of 3 quarters · filed 2017-03-01 | $15.22M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $5.97M derived: sum of 2 quarters · filed 2017-03-01 | $10.78M derived: sum of 3 quarters · filed 2017-03-01 | $17.18M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $3.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $8.00M derived: sum of 2 quarters · filed 2015-11-06 | $14.40M 10-Q · filed 2015-11-06 | $18.45M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $4.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $11.21M 10-Q · filed 2015-08-07 | $15.26M derived: sum of 3 quarters · filed 2017-03-01 | $18.47M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $6.40M 10-Q · filed 2015-05-01 | $10.45M derived: sum of 2 quarters · filed 2017-03-01 | $13.66M derived: sum of 3 quarters · filed 2017-03-01 | $14.99M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $7.26M derived: sum of 2 quarters · filed 2017-03-01 | $8.59M derived: sum of 3 quarters · filed 2017-03-01 | $10.57M 10-K · filed 2017-03-01 | |
| 2014-09-30 | $3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $4.54M derived: sum of 2 quarters · filed 2014-11-10 | $6.52M 10-Q · filed 2014-11-10 | ||
| 2014-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $3.30M 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $1.98M 10-Q · filed 2014-05-12 | ||||
| 2013-12-31 | $8.86M 10-K · filed 2017-02-22 | $8.86M 10-K · filed 2014-03-04 | |||
| 2013-09-30 | $7.18M 10-Q · filed 2013-11-08 | $9.53M derived: sum of 2 quarters · filed 2013-11-08 | $10.14M derived: sum of 3 quarters · filed 2013-11-08 | ||
| 2013-06-30 | $2.35M 10-Q · filed 2013-08-08 | $2.96M derived: sum of 2 quarters · filed 2013-08-08 | |||
| 2013-03-31 | $613.00K 10-Q · filed 2013-05-10 | ||||
| 2012-12-31 | $719.00K 10-K · filed 2015-03-13 | $718.98K 10-K · filed 2013-03-15 | |||
| 2012-09-30 | $442.23K 10-Q · filed 2012-11-13 | ||||
| 2012-06-30 | $83.00K 10-Q · filed 2012-08-14 | ||||
| 2011-12-31 | $258.00K 10-K · filed 2014-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B |